- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Everest Organics Ltd manufactures APIs and Intermediates.Product Profile: a) APIs: Company has products for Gastroenterology, Hypercholesterolemia, Benign Prostatic, Anti Convulsant, Hypertrophy, Hyperuricemia and Gout, Anti Thrombotic, Anti Fungal, Anti Viral, Anti Emetics, Anti Diabetic, Insomnia, Skeletal muscle relaxant, Overactive Bladder, Rhino-Conjunctivitis, etc.b) Intermediates: Febuxostat, Ilaprazole, Imatinib, Oseltamivir Phosphate, Abiraterone Acetate,...
Everest Organics Limited has publicly announced its financial results for the quarter ended June 30, 2026. The company disseminated these results through newspaper advertisements published in 'The South India Times' (English) and 'Telugu Prabha' (Regional). This update is crucial for shareholders and potential investors, as it provides the latest insights...
The company's Board has approved the appointment of Mr. Srikanth Reddy Kolli and Mr. Subroto Banerjee as new Independent Directors, each for a five-year term. This move strengthens governance by re-constituting crucial committees including Audit, Nomination & Remuneration, Stakeholders Relationship, and CSR. The Board also approved the annual report for...
The Board approved significant governance updates. Mr. Srikanth Reddy Kolli and Mr. Subroto Banerjee were appointed as Additional Independent Directors for five-year terms, pending shareholder consent. This led to the reconstitution of key committees, including Audit and Nomination & Remuneration. Additionally, the Board approved the annual report for financial year...